Discover how zipalertinib, an oral TKI, addresses unmet needs in treating EGFR exon 20 insertion-mutated non-small cell lung cancer.
Helena Yu, MD
Helena Yu, MD, is a medical oncologist specializing in lung cancer at Memorial Sloan Kettering Cancer Center.
Articles by Helena Yu, MD
Helena Yu, MD, discusses the importance of zipalertinib's oral administration route for patients with EGFRm non–small cell lung cancer.
Helena Yu, MD, discusses the efficacy of zipalertinib for EGFR-mutant non–small cell lung cancer and the importance of exploring therapies with CNS penetration in this space.